#ASCO22 – Estudo randomizado | Ibrutinibe com bendamustina e rituximabe no linfoma de células do manto.

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients – BTK inhibitor as front-line option for MCL – University of Texas M. D. Anderson Cancer Center

Comentário: Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma – The ASCO Post